Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (304)	8/7/2003 11:44:21 AM
From: keokalani'nui	Read Replies (1) of 824

>>It prevents deaths - just not more than 30% of the expected CABG deaths at 30 days. << Better said: It prevents deaths or MIs - just not.... It could indeed reduce death at a much greater rate than 30%, since death/MI have same formulaic value = 1, and such a finding might also be significant. We don't know since they did not mention even one p value or one individual secondary endpoint. Anyone, please comment on how statistician would discredit the fact that the larger group, the one that is more highly powered and more accurately reflects clinical practice, achieved the composite at 30 days with statistical significance? Is that (insert sneer here) some kind of subset? When you are talking about saving lives and heart tissue, who cares if the company first thought, based on previous 37 pt valve group, there was no benefit to be found in valve pts?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next